Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results by Obońska, Karolina et al.
Address for correspondence: Dr. Karolina Obońska, Department of Cardiology and Internal Medicine,  
Nicolaus Copernicus University, Collegium Medicum, ul. Skłodowskiej-Curie 9, 85–094 Bydgoszcz, Poland,  
tel: +48 52 585 40 23, fax: +48 52 585 40 24, e-mail: k.obonska@cm.umk.pl
Received: 30.05.2020 Accepted: 13.10.2020
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Low dose of ROSuvastatin in combination with 
EZEtimibe effectively and permanently reduce  
low density lipoprotein cholesterol concentration  
independently of timing of administration (ROSEZE): 
A randomized, crossover study — preliminary results
Karolina Obońska1, Michał Kasprzak1, Kamila Tymosiak1,  
Tomasz Fabiszak1, Magdalena Krintus2, Jacek Kubica1
1Department of Cardiology and Internal Medicine, Nicolaus Copernicus University,  
Collegium Medicum, Bydgoszcz, Poland 
2Department of Laboratory Medicine, Nicolaus Copernicus University,  
Collegium Medicum, Bydgoszcz, Poland
Abstract
Background: In an attempt to improve low density lipoprotein-cholesterol (LDL-C) level control in pa-
tients ineffectively treated with statins, we evaluated the effectiveness of a fixed-dose combination (FDC) 
of 10 mg rosuvastatin and ezetimibe and its relation to the timing of drug administration.
Methods: A randomized, open label, single center, crossover study involving 83 patients with coronary 
artery disease and hypercholesterolemia with baseline LDL-C ≥ 70 mg/dL. In arm I the FDC drug was 
administered in the morning for 6 weeks, then in the evening for the following 6 weeks and vice versa 
in arm II. The primary endpoint was the change in LDL-C after 6 and 12 weeks.
Results: The median LDL-C concentration at baseline, after 6 and 12 weeks respectively was:  
98.10 mg/dL (Q1;Q3: 85.10;116.80), 63.14 mg/dL (50.70;77.10) and 59.40 mg/dL (49.00;73.30);  
p < 0.001. LDL-C levels were similar regardless of the timing of drug administration (morning 62.50 
mg/dL [50.70;76.00] vs. evening 59.70 mg/dL [48.20;73.80]; p = 0.259], in both time points: 6 week: 
63.15 mg/dL (50.75;80.65) vs. 63.40 mg/dL (50.60;74.00), p = 0.775; and 12 week: 62.00 mg/dL 
(50.20;74.40) vs. 59.05 mg/dL (47.65;66.05), p = 0.362. The absolute change in LDL-C concentra-
tion for the morning vs. evening drug administration was — 6 week: –34.6 mg/dL (–56.55; –19.85) 
(–34.87%) vs. –31.10 mg/dL (–44.20; –16.00) (–35.87%) (p not significant); 12. week: –34.20 mg/dL 
(–47.8; –19.0) (–37.12%) vs. –37.20 mg/dL (–65.55; –23.85) (–40.06%) (p not significant). The therapy 
was safe and well tolerated.
Conclusions: Fixed-dose combination of rosuvastatin and ezetimibe significantly and permanently 
decreases LDL-C regardless of the timing of drug administration. (Cardiol J 2021; 28, 1: 58–66)
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Coronary artery disease (CAD) remains the 
most common single cause of death worldwide [1]. 
Hypercholesterolemia constitutes one of its major 
risk factors [2]. According to the European Society 
of Cardiology (ESC) and European Atherosclerosis 
Society (EAS) 2016 guidelines for the management 
of dyslipidemias, the therapeutic target for low 
density lipoprotein-cholesterol (LDL-C) is < 70 
mg/dL (< 1.8 mmol/L) [1, 3]. The first line treat-
ment of hypercholesterolemia is statin therapy [3]. 
However, when the therapeutic target of LDL-C 
is not achieved, the addition of cholesterol absorp-
tion inhibitor — ezetimibe — to statin therapy is 
recommended [3, 4]. Unfortunately, lipid-lowering 
therapy is discontinued in a high percentage of 
patients with CAD [5]. One year after myocardial 
infarction (MI) only approximately 50% of patients 
report persistent use of statins [6, 7]. Furthermore, 
even when patients follow the recommendations 
and continue statin therapy, only a minority obtains 
optimal level of LDL-C [8, 9]. 
The aim of the present study was to evaluate 
the effectiveness of hypercholesterolemia treat-
ment with rosuvastatin and ezetimibe in patients 
ineffectively treated with statin monotherapy. Also 
under investigation was whether the timing (morn-
ing vs. evening) of rosuvastatin and ezetimibe 
administration affects their efficacy.
Methods
Study design and population
The study was designed as a randomized, 
open-label, single-center, crossover study. It was 
conducted in accordance with the principles con-
tained in the Declaration of Helsinki and Good 
Clinical Practice guidelines and aimed to evaluate: 
the effectiveness of combined therapy with rosuv-
astatin and ezetimibe for hypercholesterolemia in 
patients with inadequate LDL-C control on statins 
alone, and to determine whether the timing of drug 
administration influences their efficacy (Clinical-
Trials.gov Identifier: NCT02772640). The study 
was approved by local institutional review board 
(The Ethics Committee of Nicolaus Copernicus 
University in Torun, Collegium Medicum in Bydgo-
szcz, Poland). All participants signed informed con-
sent prior to the performance of any investigational 
procedures. Key inclusion criteria included: diag-
nosis of hypercholesterolemia, defined according 
to the 2016 European guidelines [3], ineffectively 
treated for at least 6 weeks with statins. Patients 
eligible for the study had LDL-C ≥ 70 mg/dL. 
Major exclusion criteria included: active liver 
disease; unexplained persistent increase in serum 
transaminases activity (i.e. > 3-fold higher than the 
upper reference limit [URL]); myopathy; activity 
of creatine kinase (CK) > 5-fold higher than the 
URL. The complete list of inclusion and exclusion 
criteria has been previously published [10].
Patients hospitalized at the Department of 
Cardiology, Dr. Antoni Jurasz University Hospital 
No. 1 in Bydgoszcz, Poland, between the years 
2016 and 2018 were screened, and if eligible, were 
enrolled in the study. The diagnosis of hypercho-
lesterolemia was confirmed based on the lipid 
profile assessed during hospitalization. Patients 
with LDL-C ≥ 70 mg/dL, despite having a 6-week 
statin monotherapy, were enrolled. After enroll-
ment, all participants were randomly assigned to 
one of two study arms using Random Allocation 
Software 1.0. The study drug was a fixed dose 
combination (FDC) of rosuvastatin 10 mg and 
ezetimibe 10 mg formulated as capsules (Rosulip 
plus by Egis). In arm I, the study drug was admin-
istered in the morning (8:00 am) for 6 weeks and 
then in the evening (8:00 pm) for the next 6 weeks. 
In arm II, patients were receiving the study drug 
in the evening (8:00 pm) for the first 6 weeks and 
then in the morning (8:00 am) for the following 
6 weeks. All patients received the study drug free 
of charge over the entire observational period. The 
remaining medications were as recommended by 
the ESC guidelines accordingly to specific comor-
bidities. Clinical evaluation and blood sampling 
were performed on the day of randomization and 
after 6 and 12 weeks of treatment. In a subgroup 
of patients, blood samples were collected twice 
a day: 12 and 24 hours after the last dose of study 
drug during follow-up visits.
Endpoints
The primary outcome was defined as change 
in LDL-C after 6 and 12 weeks of the investigated 
therapy, with respect to timing of the study drug 
administration. The secondary endpoints included: 
change in total cholesterol (TC) and triglycerides 
(TG) levels after 6 and 12 weeks (also with respect 
to timing of the study drug administration), concen-
tration of high-sensitivity C-reactive protein (hs-
-CRP), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), creatine kinase (CK), 
apolipoprotein B (apoB) and lipoprotein(a) (Lp(a)) 
at baseline and after 6 and 12 weeks of the therapy.
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Blood collection and laboratory  
measurements
A detailed description of blood collection and 
laboratory measurements has been previously 
published [10]. Routine laboratory measurements 
were performed in fresh serum (basic lipid profile 
[TC, TG, LDL-C], AST, ALT, CK). The remaining 
serum was aliquoted and stored at –80°C until as-
sayed for hs-CRP, apoB, Lp(a). All measurements 
(except for CRP) were performed using the Horiba 
ABX Pentra 400 analyzer (Horiba ABX, Montpel-
lier, France). LDL-C was measured directly. CRP 
was measured using the Alinity c analyzer (Abbott 
Laboratories, Chicago, IL, USA) with the Alinity 
c CRP Vario High Sensitivity assay for the quan-
titative, immunoturbidimetric determination 
of CRP with a limit of detection of 0.4 mg/L. 
Laboratory measurements were performed at 
the Department of Laboratory Medicine, Nico-
laus Copernicus University, Collegium Medicum, 
Bydgoszcz, Poland.
Statistical analysis 
Statistical analysis was carried out using the 
Statistica 13.0 package (StatSoft, Tulsa, USA). 
The Shapiro-Wilk test demonstrated that the in-
vestigated continuous variables were not normally 
distributed. Therefore, continuous variables were 
presented as median and quartiles (lower and up-
per) and nonparametric tests (the Mann-Whitney 
unpaired rank sum test, the Wilcoxon signed rank 
test, and the Friedman ANOVA) were used for 
statistical analysis. The c2 test was used for com-
parisons of qualitative variables. Differences were 
considered statistically significant at p < 0.05.
Results
Eighty-three patients were enrolled into the 
study. The mean age was 64.6 ± 8.7 years. The 
majority of included patients had a documented 
history of CAD (93.98%) and 62.7% had prior MI. 
There were no differences between patients in both 
study arms (Table 1). At the time of enrollment, the 
majority of patients were treated with atorvastatin 
(72.29%), 16.87% used rosuvastatin, and the rest 
were treated with simvastatin.
Primary endpoint
After 6 weeks of therapy with the study drug, 
there was a significant reduction in LDL-C (median: 
98.10 mg/dL; interquartile distribution [Q1;Q3]: 
85.10;116.80 vs. 63.14 mg/dL; 50.70;77.10; 
p < 0.001). The decrease was constant over time 
after 12 weeks (63.14 mg/dL [50.70;77.10] vs. 
59.40 mg/dL [49.00;73.30]; p = 0.077; Fig. 1). 
There was no significant difference between LDL-C 
with respect to the timing of the study drug ad-
ministration (morning: 62.50 mg/dL [50.70;76.00] 
vs. evening: 59.70 mg/dL [48.20;73.80]; p = 0.259; 
Fig. 2), in both time points after 6 and 12 weeks, 
respectively (af ter 6 weeks: 63.15 mg/dL 
[50.75;80.65] vs. 63.40 mg/dL [50.60;74.00]; 
p = 0.775); af ter 12 weeks: 62.00 mg/dL 
[50.20;74.40] vs. 59.05 mg/dL [47.65;66.05]; 
p = 0.362). After 6 weeks the absolute change 
in LDL-C was –34.6 (–56.55; –19.85) (–34.87% 
[–46.83; –22.69]) for the morning administration 
of the study drug, and –31.10 (–44.20; –16.00) 
(–35.87% [–47.87; –17.96]) (p not significant) 
for the evening administration. Twelve weeks 
after, the absolute change in LDL-C was –34.20 
(–47.8; –19.0) (–37.12% [–46.18; –20.62]) for the 
morning and –37.20 (–65.55; –23.85) (40.06% 
[–55.24;–23.33]) (p not significant) for the evening 
administration, respectively.
In a subgroup of 20 patients additional measure-
ments were performed at 12 and 24 hours after the 
last dose of the study drug. In patients receiving 
the study drug in the morning, LDL-C measured 
in the evening (i.e. 12 h after the last dose) were 
significantly lower than the next morning (i.e. 24 h 
Table 1. Baseline characteristics of study patients and comparison between study arms.
Population N = 83  
patients
Group I  
(40 patients)
Group II  
(43 patients)
P
Female 20 (24.1%) 7 (17.5%) 13 (30.2%) 0.1753
Age [years] 64.6 ± 8.7 64.6 ± 7.9 64.6 ± 9.4 0.9675
Post myocardial infarction 52 (62.7%) 21 (52.5%) 31 (72.%) 0.0867
Hypertension 58 (69.9%) 24 (60.0%) 34 (70.1%) 0.0814
Heart failure 30 (36.2%) 12 (30.0%) 18 (41.9%) 0.2977
Diabetes mellitus 22 (36.5%) 9 (22.5%) 13 (30.2%) 0.4652
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after the last dose of the study drug) [52 mg/dL 
(46.95;75.85) vs. 64.95 mg/dL (50.35;77.05); 
p=0.019] (Fig. 3). Nevertheless, both results were 
significantly lower compared with baseline LDL-C 
[12 h: 93.5 mg/dL (86.15;113.4) vs. 52 mg/dL 
(46.95;75.85); p=0.000089; 24 h: 93.5 mg/dL 
(86.15;113.4) vs. 64.95 mg/dL (50.35;77.05); 
p<0.000001]. Among patients taking the drug in 
the evening, LDL-C measured next morning (i.e. 
12 h after the last dose of the study drug) was 
comparable with the LDL-C level measured in the 
evening the same day (i.e. 24 h after the last dose 
of the study drug) [61.05 mg/dL (45.85;74.05) vs. 
63.35 mg/dL (44.75;71.00); p = 0.255] (Fig. 4).
Secondary endpoints
Total cholesterol was significantly lower after 
6 weeks of therapy with the study drug and this ef-
fect was stable throughout the observational period 
(Fig. 5). Moreover, the effect was independent of 
the timing of study drug administration (Table 2). 
Similar results were achieved for TG. There was 
a significant reduction in TG concentration com-
pared with baseline values (Table 2), and the out-
come was again independent of the timing of the 
study drug administration (Table 2).
With regard to apoB, a significant reduction 
was found in its concentration after 6 weeks of 
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p = 0.259.
Figure 2. Low density lipoprotein cholesterol (LDL-C) 
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Figure 3. Morning administration of the study drug: 
change in low density lipoprotein cholesterol (LDL-C) 
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Figure 4. Evening administration of the study drug: 
change in low density lipoprotein cholesterol (LDL-C) 
concentration depending of time of testing.
Figure 1. Primary endpoint: Change in low density li-
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p < 0.00001. p = 0.077.
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104.00] vs. 68.00 [57.00;83.00]; p < 0.00001). The 
reduction was persistent throughout the observa-
tional period, and was independent of the timing of 
the study drug administration (Table 2). 
Lipoprotein(a) decreased after the study drug 
administration, however without statistical signifi-
cance (Table 2).
There was no alteration in AST activity. An 
increase in ALT activity compared with baseline 
values was recorded, regardless of the timing of 
the study drug administration. Nevertheless, the 
morning and evening measurements showed no 
significant difference (Table 2). There were no 
cases of ALT activity increase ≥ 3 × URL.
There was a statistically significant, tran-
sient increase in CK activity after initiation of 
the treatment (Table 2), always < 5 × URL. 
After 12 weeks of therapy CK activity showed 
no significant differences compared with baseline 
levels (73.0 [55.0;108.0] vs. 84.0 [60.0;125.0]; 
p = 0.245). Similar CK activity was noted regard-
less of the timing of the study drug administra-
tion (morning: 86.0 [56.0;116.0] vs. evening: 80.0 
[63.0;128.0]; p = 0.984).
High-sensitivity C-reactive protein concen-
tration was significantly reduced after 6 weeks of 
treatment (Table 2). The effect was stable through-
out the observational period (Table 2). 
Discussion
The main finding of the ROSEZE study is 
confirmation of the effectiveness and safety of 
combined therapy for hypercholesterolemia us-
ing an FDC of low dose rosuvastatin (10 mg) 
Figure 5. Change in total cholesterol (TC) concentration 
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and ezetimibe, regardless of the timing of drug 
administration, in patients unsuccessfully treated 
with statin monotherapy. According to available 
research, the current study is the first trial assess-
ing the effectiveness of an FDC of rosuvastatin and 
ezetimibe in relation to the daily timing of drug 
administration.
As demonstrated in a meta-analysis of trials 
assessing statin therapy, each 40 mg/dL drop in 
LDL-C translates into a significant reduction in 
all-cause mortality (by 10%) [11] and major car-
diovascular events (by 23%) [12]. More power-
ful statins compared with weaker ones, produce 
a highly significant 15% (95% confidence interval 
[CI] 11–18; p < 0.0001) further reduction in major 
vascular events [11]. More intensive LDL-C low-
ering therapies including potent statins alone or 
combinations of statins with ezetimibe or proprotein 
convertase subtilisin/kexin type 9 (PCSK-9) inhibi-
tors are associated with a great reduction in risk of 
total and cardiovascular mortality, especially when 
the baseline LDL-C level exceeds 100 mg/dL [13].
Surveys and national databases of patients 
with hypercholesterolemia and CAD demonstrated 
that the LDL-C target levels recommended by 2016 
ESC guidelines were achieved only in a small per-
centage of patients: 19.3% according to EUROE-
SPIRE IV [5], 19–25% according to a large real-life 
German registry from the years 2011–2016 [8] and 
were only 5.8% according to a large Italian database 
published in 2019 [9]. Other lessons coming from 
available registries include (i) too low usage of 
high intensity statins and (ii) frequently premature 
discontinuation of lipid lowering therapy (LLT). 
Several trials demonstrated the superiority 
of combined treatment of hypercholesterolemia 
with statins and ezetimibe compared with statin 
monotherapy, revealing that addition of ezetimibe 
to statin therapy provides more extensive reduc-
tion of LDL-C than doubling the statin dose, and 
thus allows more patients to achieve the LDL-C 
goal [14–16]. The IMPROVE-IT trial, demon-
strated that adding ezetimibe to low intensity 
statin (simvastatin 40 mg) carries benefit (24% of 
additional reduction in LDL-C compared with statin 
monotherapy and lowering the risk of cardiovas-
cular events compared with statin monotherapy 
with a 2.0-percentage-point lower rate of primary 
end point defined as a composite of death from 
cardiovascular disease, a major coronary event 
or nonfatal stroke [17]) independent of age [18] 
and sex [19] with a good safety profile, supporting 
the use of intensive, combined LLT to optimize 
cardiovascular outcomes [17–19]. 
In studies evaluating the effectiveness of more 
potent regimens, rosuvastatin enabled LDL-C 
reduction by 44–47% [20–22]. The PULSAR trial 
revealed that in high-risk patients with hypercho-
lesterolemia, rosuvastatin 10 mg is more efficient 
at reducing the LDL-C level than the commonly 
used 20 mg dose of atorvastatin, enabling LDL-C 
goal achievement and improving other lipid pa-
rameters [22]. In the MRS-ROZE study, Kim et 
al. [23] demonstrated that FDCs of ezetimibe and 
rosuvastatin provided superior efficacy to rosuvas-
tatin alone in lowering LDL-C, TC and TG levels 
(reduction by 56–63%, 37–43%, and 19–24%, 
respectively). 
Similarly, the I-ROSETTE trial reported the 
LDL-C lowering efficacy of each ezetimibe/rosu-
vastatin combination to be superior to each of the 
respective doses of rosuvastatin [24]. The mean 
percent change in LDL-C in all ezetimibe/rosu-
vastatin combination groups exceeded 50% [24]. 
Moreover, the number of patients who achieved 
target LDL-C levels after 8 weeks of an obser-
vational period was significantly higher in the 
combined therapy group than in the rosuvastatin 
monotherapy group (92.3% vs. 79.9%, p < 0.001) 
[24]. Rosuvastatin alone or in combination with 
ezetimibe is very effective even in patients with 
familiar hypercholesterolemia. Mickiewicz et al. 
[25] demonstrated a reduction in LDL-C concen-
tration by 45.9% and 55.4% depending whether it 
concerned monogenic or polygenic subjects with 
familiar hypercholesterolemia [25]. 
As expected, the present study also dem-
onstrated that an FDC of rosuvastatin 10 mg/ 
/ezetimibe 10 mg significantly reduces LDL-C and 
other lipid fractions including TC and TG. The 
median percentage change in LDL-C after FDC 
drug in the current study was –35–40%. It allowed 
achievement of the target LDL-C level < 70 mg/dL 
in 66.27% and 69.88% in patients receiving the FDC 
drug in the morning and in the evening, respec-
tively. Nevertheless, this result cannot be regarded 
as fully satisfactory, considering that according to 
the newly published 2019 European Guidelines 
for the Management of Dyslipidemias, the thera-
peutic goal for LDL-C in very high-risk patients 
was further lowered to the level of < 55 mg/dL 
(< 1.4 mmol/L) [4], thus the combination with 
10 mg of rosuvastatin might not be sufficient for 
every single patient. 
Apolipoprotein B, which is known to be a more 
informative marker of adequacy of statin treatment 
than LDL-C [26], similar to other studies [27–30] it 
was reduced in the present study by 26.9%, achiev-
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ing median values close to those recommended in 
the recent 2019 guidelines [4].
Nozue et al. [31] showed a potential role of 
ezetimibe as an Lp(a) lowering drug. The reduction 
in Lp(a) concentration in the current study did not 
reach statistical significance. In a meta-analysis of 
randomized controlled trials, Sahebkar et al. [32] 
demonstrated that ezetimibe in monotherapy or 
in combination with statin did not affect plasma 
Lp(a) levels.
As indicated by the present results, the daily 
timing of administration of the study drug did not 
affect its efficacy. So far, statins were commonly 
administered in the evening due to the peak of 
hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A 
(HMG-CoA) reductive activity and cholesterol syn-
thesis which occurs at night [33, 34]. Meanwhile, 
the majority of medications are taken in the morn-
ing, thus avoidance of the last pill during the day, 
which is statin in most cases, is a huge problem. 
For this reason, we investigated whether the daily 
timing of intake is relevant for lipid lowering drugs. 
Although, in our study there was no significant dif-
ference between obtained LDL-C levels according 
to the timing of study drug intake (morning vs. 
evening), the discrepancies found in LDL-C reduc-
tion depending on the time of test performance: 
12 or 24 hours after the last dose of the drug 
studied, are not completely clear and need further 
exploration. According to a research by Nishida et 
al. [35], rosuvastatin exposure decreases under 
the fed condition compared with strict fasting. 
However, it was only a pharmacokinetics study 
assessing potential food effect and the bioequiva-
lence between co-administered ezetimibe and 
rosuvastatin and FDC tablets containing ezetimibe 
and rosuvastatin in healthy Japanese subjects under 
fasted and fed conditions [35]. 
According to available research, the present 
study is the first one to reveal the influence of the 
timing of an FDC of rosuvastatin and ezetimibe on 
the effectiveness of LLT. Observations herein, indi-
cate similar potency of tested therapy, regardless of 
whether the drug was administered in the evening 
or in the morning. As a consequence of this, we en-
courage administration of the FDC of rosuvastatin 
with ezetimibe in the morning with the majority of 
other drugs. This timing modification may translate 
into better adherence to recommended LLT, com-
pared with traditional statin dosing in the evening, 
which leads to its frequent omission. Simplifying 
the treatment strategies and reducing the number 
of tablets by using polypills are one of key factors 
for better cooperation between health care provid-
ers and patients, and better drug adherence [3].
Similar to previous studies in patients with 
CAD [36, 37], in the present study, the tested 
therapy provoked a further reduction in hs-CRP 
concentration, compared with baseline values. 
Considering the fact that our population of patients 
had been already treated with statins for secondary 
prevention prior to the study, it was the addition 
of ezetimibe that led to a further reduction of the 
inflammatory process. This finding supports the ex-
istence of a pleotropic anti-inflammatory, in addition 
to hypolipemic, effect of ezetimibe, both of which 
are responsible for residual atherosclerotic risk [38].
The safety and tolerability of the tested thera-
py were similar in both arms of the current study. 
There were no cases of rosuvastatin/ezetimibe-
related adverse events including muscular, hepatic 
and gastrointestinal events.
Limitations of the study
This study has several limitations. The first 
one is a relatively small sample size. Due to the pre-
liminary nature of the study, the number of patients 
included in the current analysis is lower than calcu-
lated earlier for the sample size. Second, the study 
was designed to assess changes in LDL-C concen-
tration without addressing the relationship between 
LDL-C reduction and clinical outcomes. Third, the 
divergences between LDL-C levels assessed 12 and 
24 hours after the last dose of rosuvastatin and 
ezetimibe may have had a multifactorial origin which 
is difficult to explain at this point and would likely 
require an adequate sample size for clarification.
Conclusions
The present study demonstrates that a com-
bination of rosuvastatin and ezetimibe as a polypill 
is effective and well tolerated, showing similar 
efficacy whether administered in the morning or 
in the evening.
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